EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter experience with the Zevalin radiolabeling kit for radioimmunotherapy of non-Hodgkins lymphoma



Multicenter experience with the Zevalin radiolabeling kit for radioimmunotherapy of non-Hodgkins lymphoma



Blood 96(11 Part 2): 251b, November 16



Zevalin (ibritumomab tiuxetan) is an anti-CD20 murine IgG1 monoclonal antibody conjugated to the linker tiuxetan (MX-DTPA), which securely chelates 90Y for radioimmunotherapy (RIT). Zevalin is under investigation for the outpatient treatment of relapsed or refractory low-grade, follicular or CD20+ transformed B-cell NHL. The therapeutic Zevalin injection is preceded by two infusions of 250 mg/m2 rituximab, the unlabeled chimeric anti-CD20 antibody, to clear peripheral B cells and improve biodistribution of the radiolabeled antibody. The two rituximab infusions are separated by one week, with the second infusion delivered immediately prior to 50Y Zevalin injection. A unique radiolabeling kit is used to prepare the Zevalin dose which must be administered within 8 hours of the radiolabeling procedure. By preparing 90Y Zevalin on the same day as administration, radiolysis during shipping is avoided resulting in very high radiochemical purity (RCP). During four Phase I-III clinical trials, 215 90Y Zevalin doses were prepared at 26 clinical sites. All doses were prepared and released during a 30 minute procedure performed in the treating nuclear medicine department or an affiliated radiopharmacy. Within a glass septum reaction vial, a solution of 40 mCi 90Y was first adjusted to pH 4 with 50 mM sodium acetate. Zevalin was then transferred to the vial, incubated for 5 minutes, and the chelating reaction was terminated with a 7.5% human serum albumin formulation buffer. DTPA within the formulation buffer binds any remaining free 90Y, thus preventing nonspecific bone uptake. The 90Y Zevalin dose met RCP release criteria for patient use if instant thin-layer chromatography revealed that gtoreq 95% of 90Y was securely chelated to Zevalin. Of 215 90Y Zevalin preparations, 208 (97%) met RCP release criteria. The median RCP was 98%. An additional 195 doses of 111In Zevalin were prepared for imaging and dosimetry. Of these, 193 (99%) met RCP release criteria with a median RCP value of 99%. These results demonstrate that the Zevalin radiolabeling procedure is reliable in a multicenter setting. The user-friendly radiolabeling kit allows Zevalin to be prepared and distributed for dosimetric or therapeutic use in a timely fashion on the day of injection.

(PDF 0-2 workdays service: $29.90)

Accession: 035349848

Download citation: RISBibTeXText



Related references

Zevalin radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma. European Journal of Cancer 35(SUPPL 5): S57, 1999

Zevalin radioimmunotherapy is effective for patients with bulky non-Hodgkins lymphoma. International Journal of Radiation Oncology Biology Physics 51(3 Supplement 1): 69-70, 2001

Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkins lymphoma. Blood 96(11 Part 1): 731a, November 16, 2000

Zevalin radioimmunotherapy improves quality of life in patients with low grade, follicular, or transformed non-hodgkins lymphoma. Blood 96(11 Part 1): 734a, November 16, 2000

Zevalin radioimmunotherapy offers safe and effective therapy for relapsed or refractory, B cell non-Hodgkins lymphoma. European Journal of Cancer 37(Supplement 6): S35-S36, October, 2001

A randomized controlled trial of Zevalin radioimmunotherapy for B-cell non-Hodgkins lymphoma Biodistribution and dosimetry results. Journal of Nuclear Medicine 41(5 Suppl ): 29P, 2000

Reduced-dose Zevalin radioimmunotherapy for patients with B-cell non-Hodgkins lymphoma and mild thrombocytopenia Biodistribution and dosimetry results. Journal of Nuclear Medicine 41(5 Suppl ): 30P, 2000

Baseline peripheral blood B-cell levels correlate with disease-free interval and response to Zevalin radioimmunotherapy or relapsed non-Hodgkins lymphoma. Blood 96(11 Part 2): 252b, November 16, 2000

Zevalin radioimmunotherapy for relapsed of refractory B-cell non-Hodgkins lymphoma Interim clinical and dosimetry findings support a weight-adjusted dosing schedule. International Journal of Radiation Oncology Biology Physics 48(3 Supplement): 237-238, 2000

Yttrium-90 Zevalin Phase I Sequential Dose Radioimmunotherapy Trial of Patients with Relapsed Low Grade and Follicular B-Cell Non-Hodgkins Lymphoma Preliminary Results. Blood 100(11): Abstract No 1387, November 16, 2002

Higher doses of Rituxan alter pharmacokinetics and biodistribution of Zevalin but may increase responses; a preliminary report of a phase I study of Zevalin using a modified treatment regimen for relapsed or refractory CD20+ B-cell follicular/transformed non-Hodgkins lymphoma. Blood 102(11): 408a, November 16, 2003

A Phase I/II Trial of High-Dose Radioimmunotherapy with Zevalin in Combination with High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed B-Cell Non-Hodgkins Lymphoma. Blood 100(11): Abstract No 679, November 16, 2002

Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Seminars in Nuclear Medicine 40(2): 122-135, 2010

Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Review of Anticancer Therapy 2(5): 485-493, 2002

Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Current Pharmaceutical Biotechnology 4(4): 221-238, 2003